Bayer HealthCare, a Germany Headquarter Chemical Company, is buying Teva Pharmaceuticals, a US-based animal health business, for USD 60 million up front, plus up to USD 85 million in manufacturing and sales milestones. Bayer HealthCare maintains taking on Teva’s the animal health operation will allow the expansion of its companion (pet food) and food animal product lines in the U.S., including the introduction of anti-infective and reproductive hormones. The Teva business will be integrated into Bayer’s own animal health business.
Featured News
Warren, Banks Call for FTC Investigation of Fire Truck Market Concentration
Jul 21, 2026 by
CPI
Metro Bank Weighs £2 Billion Bid for Aldermore
Jul 21, 2026 by
CPI
EU Antitrust Probe Deepens as Cemex Receives Formal Objections
Jul 21, 2026 by
CPI
Google Settles Russian Antitrust Case, Opens Android to Rival Search Services
Jul 21, 2026 by
CPI
Kentucky Settles Antitrust Claims Against Greystar in RealPage Rent-Setting Case
Jul 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes